NGM Biopharmaceuticals Executives
NGMDelisted Stock | USD 2.50 0.14 5.30% |
NGM Biopharmaceutica employs about 138 people. The company is managed by 18 executives with a total tenure of roughly 322 years, averaging almost 17.0 years of service per executive, having 7.67 employees per reported executive. Analysis of NGM Biopharmaceutica's management performance can provide insight into the firm performance.
NGM |
NGM Biopharmaceutica Management Team Effectiveness
The company has Return on Asset of (0.3846) % which means that on every $100 spent on assets, it lost $0.3846. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6976) %, meaning that it generated no profit with money invested by stockholders. NGM Biopharmaceutica's management efficiency ratios could be used to measure how well NGM Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.NGM Biopharmaceutica Workforce Comparison
NGM Biopharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,581. NGM Biopharmaceutica holds roughly 138 in number of employees claiming about 5% of equities under Health Care industry.
NGM Biopharmaceutica Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NGM Biopharmaceutica insiders, such as employees or executives, is commonly permitted as long as it does not rely on NGM Biopharmaceutica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NGM Biopharmaceutica insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Goeddel David V over six months ago Acquisition by Goeddel David V of 5840 shares of NGM Biopharmaceutica at 0.6211 subject to Rule 16b-3 | ||
David Woodhouse over six months ago Payment of 13032 shares by David Woodhouse of NGM Biopharmaceutica subject to Rule 16b-3 | ||
Viret Jeanfrederic over six months ago Acquisition by Viret Jeanfrederic of 450000 shares of NGM Biopharmaceutica subject to Rule 16b-3 | ||
Viret Jeanfrederic over a year ago NGM Biopharmaceutica exotic insider transaction detected | ||
David Woodhouse over a year ago Acquisition by David Woodhouse of 127200 shares of NGM Biopharmaceutica subject to Rule 16b-3 |
NGM Biopharmaceutica Notable Stakeholders
A NGM Biopharmaceutica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NGM Biopharmaceutica often face trade-offs trying to please all of them. NGM Biopharmaceutica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NGM Biopharmaceutica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William JD | Executive Directors | Profile | |
Mahi Saraf | Director Culture | Profile | |
MD FACC | Chief VP | Profile | |
Valerie JD | General VP | Profile | |
Irene Perlich | Corporate VP | Profile | |
Anthony Kuhlmann | Head Property | Profile | |
Arthur Hsu | Senior Biology | Profile | |
David Woodhouse | CEO Director | Profile | |
Alex DePaoli | Chief VP | Profile | |
Brian Muma | VP Operations | Profile | |
Daniel Kaplan | Chief Officer | Profile | |
Hsiao Lieu | Chief VP | Profile | |
Jean Viret | Chief Officer | Profile | |
Jessica Ferreyra | Research Staff | Profile | |
Diana Bockus | Head Development | Profile | |
Siobhan Mangini | Principal Pres | Profile | |
Brian Schoelkopf | Sr IR | Profile | |
JinLong Chen | Chief Founder | Profile |
About NGM Biopharmaceutica Management Performance
The success or failure of an entity such as NGM Biopharmaceuticals often depends on how effective the management is. NGM Biopharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NGM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NGM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. Ngm Biopharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people.
NGM Biopharmaceutica Workforce Analysis
Traditionally, organizations such as NGM Biopharmaceutica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NGM Biopharmaceutica within its industry.NGM Biopharmaceutica Manpower Efficiency
Return on NGM Biopharmaceutica Manpower
Revenue Per Employee | 32K | |
Revenue Per Executive | 245.4K | |
Net Loss Per Employee | 1M | |
Net Loss Per Executive | 7.9M | |
Working Capital Per Employee | 988.1K | |
Working Capital Per Executive | 7.6M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |